Navigation Links
Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME)
Date:10/20/2008

CHAPEL HILL, N.C., Oct. 20 /PRNewswire/ -- With limited information on actual return on investment for expenditures toward support of Continuing Medical Education activities, pharmaceutical, biotechnology and medical device industry executives are anxious to understand the value of CME support and strategies for ensuring investments provide appropriate impact on healthcare practitioner behaviors and patient outcomes. In the recently published report by benchmarking firm, Best Practices, LLC, reviewing the CME support functions, benchmark respondents found significant opportunity for maximizing resources through centralization and innovative use of E-CME. Data from this study, "Educating the Market: Creating Value through Support of Continuing Medical Education," identified several key practices and metrics that can enable organizations to identify performance gaps and areas for improvement to better manage their CME support functions.

To view the study abstract or complimentary summary of the full report "Educating the Market: Creating Value through Support of Continuing Medical Education," click on the following link http://www3.best-in-class.com/rr971.htm .

In a benchmarking study that included such influential companies as AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson & Johnson, Merck, Pfizer, Roche, Sanofi-Aventis and Wyeth, many key questions were covered, including:

-- What is the current landscape of continuing medical education (CME) in

North America and Europe?

-- What structural forms are used to deploy CME, optimize budgets & best

deliver content?

-- How rapidly is E-CME advancing?

-- What CME delivery channels are preferred?

-- What are the current trends and future directions of CME?

Among the key topics gathered in this report are:

-- Geographic delivery of CME

-- Structural manage
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
2. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
3. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
4. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
5. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
6. Best Practice Database Supports Bio-Pharma Product Launch
7. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
8. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
9. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
10. Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
11. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3